( November 10, 2026, 11:26 AM EST) -- SILVER SPRING, Md. — Manufacturers of glucagon-like peptide-1 receptor agonist XE "glucagon-like peptide-I
receptor agonist" (GLP-1 RA) medications must add labeling warnings about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause permanent vision loss, the U.S. Food and Drug Administration announced Nov. 9....